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Abstract
Tissue accumulation of L-phenylalanine (Phe) is the biochemical hallmark of human phenylketonuria (PKU), an
inherited metabolic disorder clinically characterized by mental retardation and other neurological features. The mechanisms
of brain damage observed in this disorder are poorly understood. In the present study we investigated some oxidative stress
parameters in the brain of rats with experimental hyperphenylalaninemia. Chemiluminescence, total radical-trapping
antioxidant potential (TRAP), superoxide dismutase (SOD), catalase (CAT) and glutathione peroxidase (GSH-Px)
activities were measured in the brain of the animals. We observed that chemiluminescence is increased and TRAP is
reduced in the brain of hyperphenylalaninemic rats. Similar data were obtained in the in vitro experiments using Phe at
various concentrations. CAT activity was significantly inhibited by Phe in vitro and in vivo, whereas GSH-Px activity was
reduced in vivo but not in vitro and SOD activity was not altered by any treatment. The results indicate that oxidative
stress may be involved in the neuropathology of PKU. However, further studies are necessary to confirm and extend our
findings to the human condition and also to determine whether an antioxidant therapy may be of benefit to these
patients. ß 2002 Elsevier Science B.V. All rights reserved.
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1. Introduction
Phenylketonuria (PKU) is the most frequent inher-
ited disorder of amino acid metabolism. PKU is
caused by a severe de¢ciency of hepatic phenylala-
nine hydroxylase activity resulting in accumulation
of L-phenylalanine (Phe) and its metabolites in blood
and other tissues [1]. Permanent brain damage in this
disease has been associated with increased Phe levels
during critical periods of brain development [2,3].
Unless diagnosed and treated very early in infancy,
this condition leads to severe retardation of intellec-
tual development, neuropsychiatric symptoms and
seizures. Although long-term therapy with a Phe-re-
stricted diet may prevent these symptoms [4], intel-
lectual and school performance depend on good die-
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tary compliance, which may be di⁄cult to achieve
[5]. Therefore, it would be desirable to develop alter-
native therapeutic approaches that could counteract
the toxic e¡ects of Phe, mainly in patients with poor
compliance [6].
Some mechanisms have been proposed to explain
the pathophysiology of the neurological dysfunction
characteristic of PKU. Severe reduction in the
amount of myelin, retarded synapse formation and
decreased dendritic arborization have been described
in human and experimental PKU [7,8]. Phe a¡ects
brain protein synthesis due to polysome disaggrega-
tion and inhibition of translation initiation [9,10]. In
addition, Phe disturbs the transport of various neu-
tral amino acids into the brain, possibly reducing
their availability for protein and neurotransmitter
synthesis [11^15]. We have previously demonstrated
some biochemical alterations in the brain of hyper-
phenylalaninemic rats chronically treated with daily
administration of Phe plus K-methyl-DL-phenylala-
nine (MePhe), a phenylalanine hydroxylase inhibitor.
These alterations include reduced Na,K-ATPase
activity in the synaptic plasma membrane [16,17],
decreased high molecular mass neuro¢lament subunit
(NF-H) content and increased phosphorylation of
the 150 kDa neuro¢lament subunit (NF-M) and tu-
bulins present in the cytoskeletal fraction [18]. Fi-
nally, brain energy metabolism is impaired by Phe
in vitro [19], a fact that is also observed in patients
[20]. However, despite these studies, the mechanisms
by which Phe causes brain damage are poorly under-
stood to date.
Oxidative stress is an important event that has
been related to the pathogenesis of some diseases
a¡ecting the central nervous system such as neurode-
generative disorders, epileptic seizures, demyelination
(multiple sclerosis), dementia, and others [21,22].
This is understandable since the central nervous sys-
tem is highly sensitive to oxidative stress due to its
high oxygen consumption, its high iron and lipid
contents, especially polyunsaturated fatty acids, and
the low activity of antioxidant defenses [23].
Several authors have reported low selenium levels
in plasma of hyperphenylalaninemic patients prob-
ably secondary to the protein restricted diet imposed
to these children in order to achieve normal plasma
Phe levels [24^27]. A more recent evaluation of hy-
perphenylalaninemic patients found that, although a
normal plasma level of selenium was seen in these
patients, a signi¢cantly lower activity of erythrocyte
GSH-Px was detected [26]. Considering that selenium
is essential to GSH-Px activity, selenium supplemen-
tation of the diet of these patients should be an ad-
junct therapy in situations of selenium de¢ciency.
Another study demonstrated that PKU patients
present elevated products of lipid peroxidation in
plasma and diminished activities of plasma and
erythrocyte GSH-Px [28]. These ¢ndings indicate
that other factors may in£uence GSH-Px activity in
PKU. Moreover, decreased serum ubiquinone-10
levels were recently observed in PKU patients [29].
Therefore, oxidative stress may be related to brain
damage in PKU, but the exact mechanisms under-
lying these e¡ects remain to be elucidated.
In the present study we investigated various pa-
rameters of oxidative stress in the brain of rats sub-
jected to chemically induced hyperphenylalaninemia
(HPA), namely chemiluminescence, total radical-
trapping antioxidant potential (TRAP), superoxide
dismutase (SOD), catalase (CAT) and glutathione
peroxidase (GSH-Px) activities. We also examined
the in vitro e¡ects of Phe on the same parameters
in the brain of 6-day-old rats. The results revealed
alterations of various of these parameters, indicating
that oxidative stress may be one of the mechanisms
by which Phe provokes brain damage in PKU. Fur-
ther studies on the oxidative stress status of PKU
patients appear to be worthwhile in order to deter-
mine whether an antioxidant therapy may be of ben-
e¢t to these patients.
2. Materials and methods
2.1. Reagents and equipment
All chemicals were purchased from Sigma Chem-
ical Co. (St. Louis, MO, USA) except for the RAN-
SOD kit which was purchased from Randox (USA).
Phe and MePhe were dissolved on the day of the
experiment in distilled water for in vitro assays,
and in saline for subcutaneous administration with
the pH adjusted to 7.4 when necessary. Chemilumi-
nescence and TRAP were assayed using a beta liquid
scintillation spectrometer (Packard Tricarb 2100TR
and Wallac model 1409, respectively) and the enzyme
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activities were measured with a double-bean spectro-
photometer with temperature control (Hitachi U-
2001).
2.2. Animals
Six- to 14-day-old Wistar rats bred in the Depart-
ment of Biochemistry, UFRGS, were used. Rats
were kept with dams while receiving the drugs until
they were killed. The dams had free access to water
and to a standard commercial chow (Germani, Porto
Alegre, RS, Brazil) containing 20.5% protein (pre-
dominantly soybean), 54% carbohydrate, 4.5% ¢ber,
4% lipids, 7% ash and 10% moisture. Temperature
was maintained at 24 þ 1‡C, with a 12:12-h light/
dark cycle. The Principles of Laboratory Animal
Care (NIH publication no. 85^23, revised 1985)
were followed in all the experiments.
2.3. Tissue preparation
On the day of the experiments, animals were killed
by decapitation without anesthesia and the brain was
immediately removed. The olfactory bulbs and pons/
medulla were discarded. The rest of the brain (fore-
brain or cerebrum) was weighed and kept chilled
until homogenization. The brain was homogenized
in the incubation medium used for each technique
and centrifuged at 1000Ug for 10 min at 4‡C, and
the supernatant was immediately used for the mea-
surements. For the enzyme activity determinations,
the brain tissue was kept frozen at 374‡C for up
to 1 week.
2.4. Chemically induced HPA
We induced HPA in rats as described by Wyse et
al. [16,17]. Suckling animals received subcutaneous
injections of 2.1 Wmol Phe plus 1.6 Wmol MePhe
per gram body weight. The substances were dissolved
in saline by heating. Controls received equivalent
volumes of saline. The acute model consisted of
one injection of MePhe on the sixth day of life and
Phe on the seventh day (after a 24-h interval). To
produce the chronic HPA model, rats received the
drugs from the sixth to the 13th day. The same doses
utilized in the acute treatment were used. MePhe was
administered once a day and Phe two times daily
(with a 9-h interval). Rats were killed 14 h after
the last injection of Phe. Treated animals achieved
maximal plasma Phe levels 30 min after the subcuta-
neous injection (3.6 þ 0.2 mM). Maximal brain levels
were achieved 60 min after Phe administration
(1 þ 0.1 mmol/kg wet weight tissue). Brain Phe con-
centrations returned to normal levels 14 h after treat-
ment (0.15 þ 0.01 mmol/kg wet weight tissue).
2.5. In vitro experiments
Brain homogenates were incubated for 1 h at 37‡C
in the presence of Phe or MePhe, and controls were
incubated with medium only. The ¢nal concentra-
tions of each substance in the incubation medium
ranged from 0.5 to 5 mM. After incubation, aliquots
were taken to measure chemiluminescence and
TRAP. To test the action of Phe on the enzymatic
antioxidant defenses (CAT, SOD and GSH-Px), the
amino acid was added to the incubation medium at
the time of assay of each enzyme activity without
previous incubation with tissue homogenate.
2.6. Chemiluminescence
Samples were assayed for chemiluminescence in a
dark room by the method of Gonzalez-Flecha et al.
[30]. Incubation £asks contained 3.5 ml of medium
consisting of 20 mM sodium phosphate (pH 7.4) and
140 mM KCl. The background chemiluminescence
was measured and 0.5 ml of homogenate immedi-
ately added. Chemiluminescence was measured for
30 min at room temperature. The background chemi-
luminescence was subtracted from the total value and
the results are represented as cps per mg protein.
2.7. Total radical-trapping antioxidant potential
(TRAP)
TRAP represents the total antioxidant capacity of
the tissue and was determined by measuring the lu-
minol chemiluminescence intensity induced by 2,2P-
azo-bis(2-amidinopropane) (ABAP) [31] at room
temperature. Tissue was homogenized 1:10 (w/v) in
0.1 M glycine bu¡er, pH 8.6, which was also used to
prepare the other solutions. Four ml of 10 mM
ABAP was added to the vial and the background
chemiluminescence was measured. Ten Wl of 4 mM
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luminol was then added and the chemiluminescence
was measured. This was considered to be the initial
value. Ten Wl of 80 WM Trolox or homogenates was
added and chemiluminescence was measured until it
reached the initial levels. The addition of Trolox or
tissue homogenate to the incubation medium reduces
the chemiluminescence. The time necessary to return
to the levels present before the addition was consid-
ered to be the induction time. The induction time is
directly proportional to the antioxidant capacity of
the tissue and was compared to the induction time of
Trolox. The results are reported as nmol of trolox
per mg protein.
2.8. Catalase assay
CAT activity was assayed by the method of Aebi
[32] which is based on the disappearance of H2O2 at
240 nm. Brain tissue was homogenized 1:10 (w/v) in
10 mM potassium phosphate bu¡er, pH 7.6. One
unit is de¢ned as 1 Wmol of hydrogen peroxide con-
sumed per minute and the speci¢c activity is reported
as units per mg protein.
2.9. Superoxide dismutase assay
The assay of SOD activity was carried out with the
RANSOD kit (Randox). Cerebral tissue was homog-
enized 1:10 (w/v) in 10 mM potassium phosphate
bu¡er, pH 7.4. This method is based on the forma-
tion of red formazan from the reaction of 2-(4-iodo-
phenyl)-3-(4-nitrophenol)-5-phenyltetrazolium chlo-
ride (I.N.T.) and superoxide radical (produced in
the incubation medium from xanthine oxidase reac-
tion) which is assayed spectrophotometrically at 505
nm. The inhibition of the produced chromogen is
proportional to the activity of the SOD present in
the sample. A 50% inhibition is de¢ned as one unit of
SOD and speci¢c activity is represented as units per
mg protein.
2.10. Glutathione peroxidase assay
GSH-Px activity was measured by the method of
Wendel [33], except for the concentration of
NADPH which was adjusted to 0.1 mM after pre-
vious tests performed in our laboratory. Tissue was
homogenized 1:10 (w/v) in 10 mM potassium phos-
phate bu¡er, pH 7.6. tert-butyl-Hydroperoxide was
used as substrate. NADPH disappearance was moni-
tored with a spectrophotometer at 340 nm. One
GSH-Px unit is de¢ned as one Wmol of NADPH
consumed per minute and speci¢c activity is repre-
sented as units per mg protein.
2.11. Protein determination
Protein was measured by the method of Lowry et
al. [34] using bovine serum albumin as standard.
2.12. Statistical analysis
Data were analyzed by the Student’s t-test or by
one-way analysis of variance followed by the Duncan
multiple range test when the F value was signi¢cant.
All analyses were performed using the Statistical
Package for the Social Sciences (SPSS) software.
3. Results
3.1. Chemically induced HPA
The e¡ects of acute and chronic administration of
Phe plus MePhe on TRAP and chemiluminescence
were initially studied. Fig. 1 shows that TRAP was
signi¢cantly decreased in brain homogenates from
rats acutely (t(12) = 4.95; P6 0.01) and chronically
treated (t(12) = 4.19; P6 0.01) with Phe plus MePhe,
Fig. 1. E¡ect of acute or chronic administration of L-phenylala-
nine plus K-methyl-DL-phenylalanine on total radical-trapping
antioxidant potential (TRAP) in brain homogenates from 14-
day-old rats. Results are mean þ S.D. for seven independent ex-
periments performed in duplicate. TRAP is calculated as nmol
of trolox per mg protein. **P6 0.01 compared to control (Stu-
dent t-test).
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as compared to control rats injected with saline. In
contrast, chemiluminescence in brain homogenates
from rats submitted to the acute (t(10) = 3.87;
P6 0.01) and chronic (t(10) = 4.46; P6 0.01) HPA
model was signi¢cantly increased compared to sa-
line-treated animals (Fig. 2).
Furthermore, brain CAT activity (Fig. 3) was not
altered in the acute HPA model (t(10) = 0.33;
Ps 0.05) but was strongly reduced in chronically
treated rats (t(10) = 2.76; P6 0.05). In turn, the ac-
tivity of SOD in the homogenates was not a¡ected
by the acute (t(12) = 0.52; Ps 0.05) or chronic HPA
model (t(12) = 1.79; Ps 0.05), as shown in Fig. 4.
Finally, rats subjected to the acute (t(12) = 5.43;
P6 0.01) and chronic (t(12) = 3.54; P6 0.01) treat-
ments showed a signi¢cant decrease in brain GSH-
Px activity (Fig. 5).
3.2. In vitro experiments
Next, we tested the in vitro e¡ect of Phe at con-
centrations resembling those found in PKU patients
on TRAP and chemiluminescence (Table 1). We
observed that Phe at concentrations of 1 mM and
higher signi¢cantly diminished the antioxidant
capacity (TRAP) of brain homogenates after 1 h
incubation (F(4,25) = 3.60; P6 0.05) and stimulated
chemiluminescence (F(4,25) = 15.60; P6 0.001) in
brain homogenates from 6-day-old rats. Moreover,
we also observed a signi¢cantly inverse correlation
between chemiluminescence and TRAP (r2 =30.79;
P6 0.01), as illustrated in Fig. 6. These results
Fig. 2. E¡ect of acute or chronic administration of L-phenylala-
nine plus K-methyl-DL-phenylalanine on chemiluminescence in
brain homogenates from 14-day-old rats. Results are mean þ
S.D. for six independent experiments performed in duplicate.
**P6 0.01 compared to control (Student’s t-test).
Fig. 3. E¡ect of acute or chronic administration of L-phenylala-
nine plus K-methyl-DL-phenylalanine on catalase activity in
brain homogenates from 14-day-old rats. Results are mean þ
S.D. for six independent experiments performed in duplicate.
One catalase unit is de¢ned as one Wmol of H2O2 consumed
per minute. *P6 0.05 compared to control (Student’s t-test).
Fig. 4. E¡ect of acute or chronic administration of L-phenylala-
nine plus K-methyl-DL-phenylalanine on superoxide dismutase
(SOD) activity in brain homogenates from 14-day-old rats. Re-
sults are mean þ S.D. for seven independent experiments per-
formed in duplicate. One SOD unit is de¢ned as 50% inhibition
of red formazan formation. No signi¢cant di¡erences from con-
trols were detected by the Student’s t-test.
Fig. 5. E¡ect of acute or chronic administration of L-phenylala-
nine plus K-methyl-DL-phenylalanine on glutathione peroxidase
(GSH-Px) activity in brain homogenates from 14-day-old rats.
Results are mean þ S.D. for seven independent experiments per-
formed in duplicate. One GSH-Px unit is de¢ned as one Wmol
of NADPH consumed per minute. **P6 0.01 compared to con-
trol (Student’s t-test).
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strongly indicate that Phe increases the in vitro oxi-
dative stress in brain from young rats.
To study the mechanisms by which Phe reduces
the antioxidant capacity when administered to rats,
we tested the e¡ect of this amino acid on the activity
of the principal enzymes responsible for the antioxi-
dant defense in the brain homogenates from 6-day-
old rats (Table 2). CAT activity was strongly inhib-
ited by Phe at all concentrations used
(F(4,15) = 90.36; P6 0.001), whereas the activities
of SOD (F(4,15) = 1.26; Ps 0.05) and GSH-Px
(F(4,30) = 1.17; Ps 0.05) were not altered by the
presence of Phe in the incubation medium.
We also studied the in vitro e¡ect of a high con-
centration (5 mM) of MePhe, the inhibitor of phenyl-
alanine hydroxylase activity used together with Phe
to induce experimental HPA in rats, on these param-
eters. The results obtained for ¢ve rats (mean þ S.D.)
revealed that MePhe does not alter the antioxidant
capacity (control: 9.37 þ 0.9 nmol trolox/mg protein;
MePhe 8.79 þ 0.68 nmol trolox/mg protein;
t(8) = 1.33; Ps 0.05) or the chemiluminescence (con-
trol : 2816 þ 223 cps/mg protein; MePhe 2930 þ 184
cps/mg protein; t(8) = 0.75; Ps 0.05), suggesting
that MePhe by itself does not interfere with the oxi-
dative stress parameters measured.
4. Discussion
Phenylketonuric patients are clinically character-
ized by marked neurological dysfunction which is
usually related to tissue Phe levels. Therefore, early
institution of a therapy based on a Phe-restricted diet
was developed by Bickel and coworkers in 1953 and
proved to e¡ectively prevent the mental retardation
of a¡ected individuals [35^37]. These observations
and the ¢ndings that Phe derivatives do not reach
toxic levels in brain indicate that Phe is the main
neurotoxic agent in PKU [1,38]. However, although
neurologic symptoms predominate, the underlying
mechanisms responsible for brain damage seem to
be multiple and have not been completely elucidated.
Furthermore, despite the apparently appropriate
Phe-restricted diet, some patients present poor intel-
lectual and school performance for reasons not yet
understood, a fact indicating that new therapeutic
approaches should be devised to treat phenylketonu-
ric patients [6,40^42].
Increased plasma malondialdehyde levels, as well
as reduced blood selenium content and GSH-Px ac-
tivity, have been recently described in hyperphenyla-
laninemic patients [26,28]. However, no symptoms
observed in these patients could be directly attributed
Table 1
In vitro e¡ect of L-phenylalanine on total radical-trapping antioxidant potential (TRAP) and chemiluminescence in brain homogenates
from 6-day-old rats
L-Phenylalanine concentration (mM)
0 0.5 1.0 2.5 5.0
TRAP (n = 6) 15.7 þ 0.9 13.1 þ 2.0 8.9 þ 2.9* 8.1 þ 2.9* 6.7 þ 2.95*
Chemiluminescence (n = 6) 2234 þ 300 2454 þ 390 2974 þ 436* 3184 þ 328* 4276 þ 302**
Results are mean þ S.D. for experiments performed in duplicate. TRAP is calculated as nmol of trolox per mg protein and chemilumi-
nescence is calculated as cps per mg protein. *P6 0.05, **P6 0.01 compared to control (Duncan multiple range test).
Table 2
In vitro e¡ect of L-phenylalanine on antioxidant enzyme activities in brain homogenates from 6-day-old rats
Enzyme activities (units/mg protein) L-Phenylalanine concentration (mM)
0 0.5 1.0 2.5 5.0
CAT (n = 4) 7.0 þ 0.9 1.6 þ 0.5 * 2.0 þ 0.5 * 3.1 þ 0.5 * 1.7 þ 0.5 *
SOD (n = 4) 84.2 þ 4.1 84.3 þ 3.3 80.4 þ 5.9 82.0 þ 2.8 83.1 þ 1.6
GSH-Px (n = 7) 5.9 þ 0.8 4.8 þ 1.4 5.4 þ 1.0 5.4 þ 1.3 4.7 þ 1.3
Results are mean þ S.D. for experiments performed in duplicate. One CAT unit is de¢ned as 1 Wmol of H2O2 consumed per minute.
One SOD unit is de¢ned as 50% inhibition of red formazan formation. One GSH-Px unit is de¢ned as 1 Wmol of NADPH consumed
per minute. *P6 0.01 compared to control (Duncan multiple range test).
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to selenium de¢ciency [28]. Furthermore, the low ac-
tivities of erythrocyte GSH-Px observed in many hy-
perphenylalaninemic patients were not altered by the
selenium-supplemented formulas employed, suggest-
ing the absence of a cause/e¡ect relationship between
plasma selenium levels and erythrocyte GSH-Px ac-
tivity [26]. The same authors also observed that neu-
rological disturbances were more frequent in these
patients than in those with normal GSH-Px activity.
Another interesting result is that ubiquinone-10, a
substance with antioxidant action, is found at de-
creased concentrations in serum of PKU patients
[29].
We decided to study a few oxidative stress param-
eters in brain of rats subjected to the widely used
HPA model based on the administration of Phe
plus MePhe, a phenylalanine hydroxylase inhibitor
[43,44]. This Phe analogue has been tested by others
on many neurochemical parameters and was consid-
ered a low-toxic agent compared to the other phenyl-
alanine hydroxylase inhibitor, p-chlorophenylalanine
[44].
In this study, we have demonstrated that chemilu-
minescence is signi¢cantly increased and TRAP is
reduced in brain of hyperphenylalaninemic rats, in-
dicating that chemical treatment with Phe plus
MePhe induced oxidative stress in the animals. Since
the in vitro experiments revealed that MePhe does
not alter these parameters and that Phe increased
chemiluminescence and reduced TRAP in vitro in
brain homogenates, we presume that Phe induces
free radical production and compromises the total
antioxidant capacity of the nervous tissue. Moreover,
the alteration of both parameters in a similar fashion
is strongly indicative of oxidative stress since this
process is de¢ned as the imbalance between free rad-
ical production and antioxidant defenses. At this
point it should be emphasized the low cerebral anti-
oxidant defenses [23], a fact that makes this tissue
more vulnerable to increases of reactive oxygen spe-
cies. In fact, an increasing number of pathological
situations involving the CNS, such as neurodegener-
ative disorders, seizures, ischemia/reperfusion, and
dementia, have been associated with oxidative stress
[22].
The enzymes CAT, SOD and GSH-Px are consid-
ered to be the main enzymatic defenses of the brain
against free radical production. We therefore tested
the e¡ects of the acute and chronic HPA models and
also the in vitro e¡ect of Phe on these enzyme activ-
ities. CAT activity was signi¢cantly inhibited by Phe
both in vitro (up to 77%) and in vivo in the chronic
HPA model (55%), but not in the acute one. Regard-
ing the mechanisms by which Phe inhibits CAT ac-
tivity, the in vitro ¢ndings probably indicate a direct
interaction of the amino acid with the enzyme inhib-
iting its activity. On the other hand, apart from act-
ing directly on the enzyme, speculatively Phe could
also have an indirect e¡ect in chronic in vivo studies
at the transcription level, blocking CAT enzyme syn-
thesis, or otherwise increasing its degradation.
SOD activity was not a¡ected in vivo or in vitro
by Phe, a fact indicating the speci¢city of the amino
acid e¡ect. On the other hand, Phe inhibited GSH-Px
activity in the chronic and acute in vivo model of
HPA, but not in vitro. These ¢ndings suggest an
indirect action of Phe, not present in the homoge-
nates, on this enzyme activity. Again, one possibility
could be an action of Phe on the enzyme turnover
a¡ecting the synthesis and/or the degradation pro-
cesses of GSH-Px. Considering the results of Phe
action on CAT and on GSH-Px activities as a whole,
we may presume that Phe administration gives rise to
a high concentration of hydrogen peroxide in the
brain of the animals, secondarily leading to brain
damage [45].
The present results strongly indicate that Phe stim-
ulates oxidative stress in the brain of hyperphenyla-
Fig. 6. Correlation between chemiluminescence and total radi-
cal-trapping antioxidant potential (TRAP) in brain homoge-
nates from 6-day-old rats. Data were taken from experiments
on the in vitro e¡ect of L-phenylalanine (Table 1). The asterisk
indicates a statistically signi¢cant correlation.
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laninemic rats and are in agreement with other ¢nd-
ings observed in PKU patients. These ¢ndings in-
clude increased products of lipid peroxidation found
in plasma and reduced activity of GSH-Px in plasma
and erythrocytes of PKU patients [26,28]. Further-
more, normal SOD activity was observed in these
patients [46], which is also in line with our results.
The concentrations of Phe at which the e¡ects
were caused in this study were similar to those ob-
served in PKU patients [1,39,42,47,48]. Even so, it is
di⁄cult to extrapolate our ¢ndings to the human
condition. However, if the e¡ects here detected also
occur in the brain of phenylketonuric patients, it is
possible that they may contribute, at least in part, to
the acute and chronic neurological dysfunction char-
acteristic of this disease. Therefore, the institution of
antioxidant therapy in PKU may be of interest to
test whether the a¡ected patients will bene¢t from
this therapy which could possibly be an adjuvant to
the commonly used Phe-restricted diet.
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